Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2010 Mar 17;29(4):6S9–6S18. doi: 10.1016/S1262-3636(03)72783-9

The burden of type 2 diabetes: are we doing enough?

P Zimmet 1,⁎
PMCID: PMC7129589  PMID: 14502096

Summary

Increasing levels of obesity, arising from energy-rich diets and sedentary lifestyles, are driving a global pandemic of type 2 diabetes. The prevalence of type 2 diabetes worldwide is set to increase from its present level of 150 million, to 225 million by the end of the decade and to as many as 300 million by 2025. Shocking as they are, these figures represent only clinically diagnosed diabetes, and many more cases of diabetes remain undiagnosed and untreated. In addition, up to one-quarter of western populations have impaired glucose tolerance or the dysmetabolic syndrome, which are considered to represent pre-diabetic states. Type 2 diabetes is appearing increasingly in children and adolescents, and the frequency of diagnosis of paediatric type 2 diabetes is outstripping that of type 1 diabetes in some areas. The long-term complications associated with type 2 diabetes carries a crushing burden of morbidity and mortality, and most type 2 diabetic patients die prematurely from a cardiovascular event. Diabetic patients are more than twice as costly to manage as non-diabetic patients, due mainly to the high costs associated with management of diabetic complications. Indeed, diabetes care already accounts for about 2-7% of the total national health care budgets of western European countries. Controlling the type 2 diabetes epidemic will require changes to the structure of healthcare delivery. Well-resourced interventions will be required, with effective co-ordination between all levels of government, health care agencies, multidisciplinary health care teams, professional organisations, and patient advocacy groups. Above all, intervention is needed today.

Key-words: Type 2 diabetes, Health economics, Cardiovascular disease, Quality of life, Diabetic complications

References

  • 1.Bennett P.H., Burch T.A., Miller M. Diabetes mellitus in American (Pima) Indians. Lancet. 1971;2:125–128. doi: 10.1016/s0140-6736(71)92303-8. [DOI] [PubMed] [Google Scholar]
  • 2.Zimmet P., Taft P., Guinea A., Guthrie W., Thoma K. The high prevalence of diabetes mellitus on a Central Pacific Island. Diabetologia. 1977;13:111–115. doi: 10.1007/BF00745137. [DOI] [PubMed] [Google Scholar]
  • 3.Zimmet P., Taft P. The high prevalence of diabetes mellitus in Nauru, a Central Pacific island. Adv Metab Disord. 1978;9:225–240. doi: 10.1016/b978-0-12-027309-6.50016-1. [DOI] [PubMed] [Google Scholar]
  • 4.Lee E.T., Cowan L.D., Welty T.K. All-cause mortality and cardiovascular disease mortality in three American Indian populations, aged 45-74 years, 1984-1988. The Strong Heart Study. Am J Epidemiol. 1998;147:995–1008. doi: 10.1093/oxfordjournals.aje.a009406. [DOI] [PubMed] [Google Scholar]
  • 5.Black S.A., Ray L.A., Markides K.S. The prevalence and health burden of self-reported diabetes in older Mexican Americans: findings from the Hispanic established populations for epidemiologic studies of the elderly. Am J Public Health. 1999;89:546–552. doi: 10.2105/ajph.89.4.546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Boyle J.P., Engelgau M.M., Thompson T.J. Estimating prevalence of type 1 and type 2 diabetes in a population of African Americans with diabetes mellitus. Am J Epidemiol. 1999;149:55–63. doi: 10.1093/oxfordjournals.aje.a009728. [DOI] [PubMed] [Google Scholar]
  • 7.Gardner L.I., Jr, Stern M.P., Haffner S.M. Prevalence of diabetes in Mexican Americans. Relationship to percent of gene pool derived from native American sources. Diabetes. 1984;33:86–92. doi: 10.2337/diab.33.1.86. [DOI] [PubMed] [Google Scholar]
  • 8.Harris S.B., Gittelsohn J., Hanley A. The prevalence of NIDDM and associated risk factors in native Canadians. Diabetes Care. 1997;20:185–187. doi: 10.2337/diacare.20.2.185. [DOI] [PubMed] [Google Scholar]
  • 9.Rowley K.G., O’Dea K. Diabetes in Australian aboriginal and Torres Strait Islander peoples. P N G Med J. 2001;44:164–170. [PubMed] [Google Scholar]
  • 10.Rush E.C., Plank L.D., Mitchelson E., Laulu M.S. Central obesity and risk for type 2 diabetes in Maori, Pacific, and European young men in New Zealand. Food Nutr Bull. 2002;23(suppl. 3):82–86. [PubMed] [Google Scholar]
  • 11.Moore M.P., Lunt H. Diabetes in New Zealand. Diabetes Res Clin Pract. 2000;50(suppl. 2):S65–S71. doi: 10.1016/s0168-8227(00)00181-9. [DOI] [PubMed] [Google Scholar]
  • 12.Amos A.F., McCarty D.J., Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;14(suppl. 5):S1–S85. [PubMed] [Google Scholar]
  • 13.King H., Aubert R.E., Herman W.H. Global burden of diabetes 1995-2025. Diabetes Care. 1998;21:1414–1431. doi: 10.2337/diacare.21.9.1414. [DOI] [PubMed] [Google Scholar]
  • 14.Zimmet P., Alberti K.G.M.M., Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–787. doi: 10.1038/414782a. [DOI] [PubMed] [Google Scholar]
  • 15.Alwan A., King H. Diabetes in the eastern Mediterranean region. World Health Stat Q. 1992;45:355–359. [PubMed] [Google Scholar]
  • 16.Asfour M., Lambourne A., Soliman A. High prevalence of diabetes mellitus and impaired glucose tolerance in the Sultanate of Oman: results of the 1991 national survey. Diabet Med. 1995;12:1122–1125. doi: 10.1111/j.1464-5491.1995.tb00431.x. [DOI] [PubMed] [Google Scholar]
  • 17.O’Dea K. Westernization and non-insulin-dependent diabetes in Australian Aborigines. Ethn Dis. 1991;1:171–187. [PubMed] [Google Scholar]
  • 18.Dunstan D.W., Zimmet P.Z., Welborn T.A. The rising prevalence of diabetes and impaired glucose tolerance. The Australian diabetes, obesity and lifestyle study. Diabetes Care. 2002;25:829–834. doi: 10.2337/diacare.25.5.829. [DOI] [PubMed] [Google Scholar]
  • 19.Dowse G.K., Gareeboo H., Zimmet P.Z. High prevalence of NIDDM and impaired glucose tolerance in Indian. Creole and Chinese Mauritians. Diabetes. 1990;39:390–396. doi: 10.2337/diab.39.3.390. [DOI] [PubMed] [Google Scholar]
  • 20.Knowler W.C., Bennett P.H., Hamman R.F., Miller M. Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester. Minnesota. Am J Epidemiol. 1978;108:497–505. doi: 10.1093/oxfordjournals.aje.a112648. [DOI] [PubMed] [Google Scholar]
  • 21.Harris M.I., Goldstein D.E., Flegal K.M. Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in US Adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518–524. doi: 10.2337/diacare.21.4.518. [DOI] [PubMed] [Google Scholar]
  • 22.Pan X.R., Yang W.Y., Li G.W., Liu J. Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. Diabetes Care. 1997;20:1664–1669. doi: 10.2337/diacare.20.11.1664. [DOI] [PubMed] [Google Scholar]
  • 23.Ramachandran A., Snehalatha C., Latha E., Vijay V., Viswanathan M. Rising prevalence of NIDDM in an urban population in India. Diabetologia. 1997;40:232–237. doi: 10.1007/s001250050668. [DOI] [PubMed] [Google Scholar]
  • 24.Drivsholm T., Ibsen H., Schroll M., Davidsen M., Borch-Johnsen K. Increasing prevalence of diabetes mellitus and impaired glucose tolerance among 60-year-old Danes. Diabet Med. 2001;18:126–132. doi: 10.1046/j.1464-5491.2001.00417.x. [DOI] [PubMed] [Google Scholar]
  • 25.Zimmet P.Z., McCarty D.J., de Courten M.P. The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome. J Diabetes Complic. 1997;11:60–68. doi: 10.1016/s1056-8727(96)00090-6. [DOI] [PubMed] [Google Scholar]
  • 26.Dowse G.K., Spark R.A., Mavo B. Extraordinary prevalence of non-insulin-dependent diabetes mellitus and bimodal plasma glucose distribution in the Wanigela people of Papua New Guinea. Med J Aust. 1994;160:767–774. doi: 10.5694/j.1326-5377.1994.tb125945.x. [DOI] [PubMed] [Google Scholar]
  • 27.Shaw J.E., Zimmet P.Z., de Courten M. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care. 1999;22:399–402. doi: 10.2337/diacare.22.3.399. [DOI] [PubMed] [Google Scholar]
  • 28.Shaw J.E., Zimmet P.Z., Hodge A.M. Impaired fasting glucose: how low should it go? Diabetes Care. 2000;23:34–39. doi: 10.2337/diacare.23.1.34. [DOI] [PubMed] [Google Scholar]
  • 29.Lee W.R. The changing demography of diabetes mellitus in Singapore. Diabetes Res Clin Pract. 2000;50(suppl. 2):S35–S39. doi: 10.1016/s0168-8227(00)00184-4. [DOI] [PubMed] [Google Scholar]
  • 30.Chang C., Lu F., Yang Y.C. Epidemiologic study of type 2 diabetes in Taiwan. Diabetes Res Clin Pract. 2000;50(suppl. 2):S49–S59. doi: 10.1016/s0168-8227(00)00179-0. [DOI] [PubMed] [Google Scholar]
  • 31.King H., Rewers M. WHO Ad Hoc Diabetes Reporting Group: global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care. 1993;16:157–177. doi: 10.2337/diacare.16.1.157. [DOI] [PubMed] [Google Scholar]
  • 32.Aschner P. Diabetes trends in Latin America. Diabetes Metab Res Rev. 2002;18(suppl. 3):S27–31. doi: 10.1002/dmrr.280. [DOI] [PubMed] [Google Scholar]
  • 33.Motala A.A. Diabetes trends in Africa. Diabetes Metab Res Rev. 2002;18(suppl. 3):S14–20. doi: 10.1002/dmrr.284. [DOI] [PubMed] [Google Scholar]
  • 34.Mokdad A.S., Ford E.H., Bowman B.A. Diabetes trends in the US: 1990-1998. Diabetes Care. 2000;23:1278–1283. doi: 10.2337/diacare.23.9.1278. [DOI] [PubMed] [Google Scholar]
  • 35.Bosello O., Zamboni M. Visceral obesity and metabolic syndrome. Obes Rev. 2000;1:47–56. doi: 10.1046/j.1467-789x.2000.00008.x. [DOI] [PubMed] [Google Scholar]
  • 36.Laaksonen D.E., Lakka H.M., Niskanen L.K., Kaplan G.A., Salonen J.T., Lakka T.A. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070–1077. doi: 10.1093/aje/kwf145. [DOI] [PubMed] [Google Scholar]
  • 37.DeFronzo R.A., Bonnadonna R.C., Ferrannini E. Pathogenesis of NIDDM A balanced overview. Diabetes Care. 1992;15:318–368. doi: 10.2337/diacare.15.3.318. [DOI] [PubMed] [Google Scholar]
  • 38.DeFronzo R.A. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med. 1997;50:191–197. doi: 10.1016/s0300-2977(97)00012-0. [DOI] [PubMed] [Google Scholar]
  • 39.Balkau B., Charles M.A., Drivsholm T. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab. 2002;28:364–376. [PubMed] [Google Scholar]
  • 40.Unwin N., Shaw J., Zimmet P., Alberti K.G.M.M. Impaired glucose tolerance and impaired fasting glycaemia: the current status of definition and intervention. Diabet Med. 2002;19:708–723. doi: 10.1046/j.1464-5491.2002.00835.x. [DOI] [PubMed] [Google Scholar]
  • 41.Köhler C., Temelkova-Kurktschiev T., Schaper F. Prevalence of newly diagnosed type 2 diabetes, impaired glucose tolerance and abnormal fasting glucose in a high risk population. Data from the RIAD study using new diagnostic criteria for diabetes. Dtsch Med Wochenschr. 1999;124:1057–1061. doi: 10.1055/s-2007-1024481. [DOI] [PubMed] [Google Scholar]
  • 42.Edelstein S.L., Knowler W.C., Bain R.P. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes. 1997;46:701–710. doi: 10.2337/diab.46.4.701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Ramachandran A., Snehalatha C., Vijay V. Temporal changes in prevalence of type 2 diabetes and impaired glucose tolerance in urban southern India. Diabetes Res Clin Pract. 2002;58:55–60. doi: 10.1016/s0168-8227(02)00125-0. [DOI] [PubMed] [Google Scholar]
  • 44.Ramachandran A., Snehalatha C., Latha E., Manoharan M., Vijay V. Impacts of urbanisation on the lifestyle and on the prevalence of diabetes in native Asian Indian population. Diabetes Res Clin Pract. 1999;44:207–213. doi: 10.1016/s0168-8227(99)00024-8. [DOI] [PubMed] [Google Scholar]
  • 45.Ramachandran A., Snehalatha C., Kapur A. High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia. 2001;44:1094–1101. doi: 10.1007/s001250100627. [DOI] [PubMed] [Google Scholar]
  • 46.Landman J., Cruickshank J.K. A review of ethnicity, health and nutrition- related diseases in relation to migration in the United Kingdom. Public Health Nutr. 2001;4:647–657. doi: 10.1079/phn2001148. [DOI] [PubMed] [Google Scholar]
  • 47.Burden A.C. Blood pressure control and cardiovascular risk in patients of Indo-Asian and African-Caribbean descent. Int J Clin Pract. 1998;52:388–394. [PubMed] [Google Scholar]
  • 48.Feltbower R.G., Bodansky H.J., McKinney P.A., Houghton J., Stephenson C.R., Haigh D. Trends in the incidence of childhood diabetes in south Asians and other children in Bradford. UK. Diabet Med. 2002;19:162–166. doi: 10.1046/j.1464-5491.2002.00691.x. [DOI] [PubMed] [Google Scholar]
  • 49.Whincup P.H., Gilg J.A., Papacosta O. Early evidence of ethnic differences in cardiovascular risk: cross sectional comparison of British South Asian and white children. Br Med J. 2002;324:625–626. doi: 10.1136/bmj.324.7338.635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.de Courten M., Bennett P.H., Tuomilehto J., Zimmet P. Epidemiology of NIDDM in non-Europids. In: Alberti K.G.M.M., Zimmet P., DeFronzo R.A., Keen H., editors. International Textbook of Diabetes Mellitus. 2nd edn. John Wiley & Sons Ltd; Chichester: 1997. pp. 143–170. [Google Scholar]
  • 51.Passa P. Diabetes trends in Europe. Diabetes Metab Res Rev. 2002;18(suppl. 3):S3–S8. doi: 10.1002/dmrr.276. [DOI] [PubMed] [Google Scholar]
  • 52.Rathmann W., Icks A., Haastert B., Giani G., Lowel H., Mielck A. Undiagnosed diabetes mellitus among patients with prior myocardial infarction. Z Kardiol. 2002;91:620–625. doi: 10.1007/s00392-002-0826-y. [DOI] [PubMed] [Google Scholar]
  • 53.Taubert G., Winkelmann B.R., Schleiffer T. Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3,266 patients scheduled for coronary angiography. Am Heart J. 2003;145:285–291. doi: 10.1067/mhj.2003.134. [DOI] [PubMed] [Google Scholar]
  • 54.Riste L., Khan F., Cruickshank K. High prevalence of type 2 diabetes in all ethnic groups, including Europeans, in a British inner city: relative poverty, history, inactivity, or 21st century Europe? Diabetes Care. 2001;24:1377–1383. doi: 10.2337/diacare.24.8.1377. [DOI] [PubMed] [Google Scholar]
  • 55.Franse L.V., Di Bari M., Shorr R.I. Type 2 diabetes in older wellfunctioning people: who is undiagnosed? Data from the Health, Aging, and Body Composition study. Diabetes Care. 2001;24:2065–2070. doi: 10.2337/diacare.24.12.2065. [DOI] [PubMed] [Google Scholar]
  • 56.Fagot-Campagna A. Emergence of type 2 diabetes mellitus in children: epidemiological evidence. J Pediatr Endocrinol Metab. 2000;13(suppl. 6):1395–1402. doi: 10.1515/jpem-2000-s613. [DOI] [PubMed] [Google Scholar]
  • 57.Dabelea D., Hanson R.L., Bennett P.H., Roumain J., Knowler W.C., Pettitt D.J. Increasing prevalence of type II diabetes in American Indian children. Diabetologia. 1998;41:904–910. doi: 10.1007/s001250051006. [DOI] [PubMed] [Google Scholar]
  • 58.Cockram C.S. The epidemiology of diabetes mellitus in the Asia- Pacific region. Hong Kong Med J. 2000;6:43–52. [PubMed] [Google Scholar]
  • 59.Silink M. Childhood diabetes: a global perspective. Horm Res. 2002;57(suppl. 1):1–5. doi: 10.1159/000053304. [DOI] [PubMed] [Google Scholar]
  • 60.Arslanian S. Type 2 diabetes in children: clinical aspects and risk factors. Horm Res. 2002;57(suppl. 1):19–28. doi: 10.1159/000053308. [DOI] [PubMed] [Google Scholar]
  • 61.Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1987;30:123–131. doi: 10.1007/BF00274216. [DOI] [PubMed] [Google Scholar]
  • 62.Zimmet P.Z., Alberti K.G.M.M. The changing face of macrovascular disease in non-insulin dependent diabetes mellitus in different cultures: an epidemic in progress. Lancet. 1997;350(suppl. 1):S1–S4. doi: 10.1016/s0140-6736(97)90020-9. [DOI] [PubMed] [Google Scholar]
  • 63.Haffner S.M., Lehto S., Rönemaa T., Pyörälä K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234. doi: 10.1056/NEJM199807233390404. [DOI] [PubMed] [Google Scholar]
  • 64.UK Prospective Diabetes Study Group Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–853. [PubMed] [Google Scholar]
  • 65.Liebl A., Neiss A., Spannheimer A. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany-results from the CODE-2 study. Exp Clin Endocrinol Diabetes. 2002;110:10–16. doi: 10.1055/s-2002-19988. [DOI] [PubMed] [Google Scholar]
  • 66.Joss N., Paterson K.R., Deighan C.J., Simpson K., Boulton-Jones M. Vascular disease and survival in patients with type 2 diabetes and nephropathy. Br J Diabetes Vasc Dis. 2002;2:137–142. [Google Scholar]
  • 67.Rajala U., Koskella P., Pajunpää H., Keinänen-Kiukaaniemi S. High cardiovascular disease mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care. 2000;23:957–961. doi: 10.2337/diacare.23.7.957. [DOI] [PubMed] [Google Scholar]
  • 68.Skyler J.S., Oddo C. Diabetes trends in the USA. Diabetes Metab Res Rev. 2002;18:S21–26. doi: 10.1002/dmrr.289. [DOI] [PubMed] [Google Scholar]
  • 69.Nichols G.A., Glauber H.S., Brown J.B. Type 2 diabetes: incremental medical care costs during the 8 years preceding diagnosis. Diabetes Care. 2000;23:1654–1659. doi: 10.2337/diacare.23.11.1654. [DOI] [PubMed] [Google Scholar]
  • 70.Brown J.B., Nichols G.A., Glauber H.S., Bakst A.W. Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. Diabetes Care. 1999;22:1116–1124. doi: 10.2337/diacare.22.7.1116. [DOI] [PubMed] [Google Scholar]
  • 71.Gray A., Raikou M., McGuire A. Cost-effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) Br Med J. 2000;329:1375–1378. doi: 10.1136/bmj.320.7246.1373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Clarke P., Gray A., Adler A. Cost-effectiveness analysis of intensive blood glucose control with metformin in overweight patients with type 2 diabetes (UKPDS 51) Diabetologia. 2000;44:298–304. doi: 10.1007/s001250051617. [DOI] [PubMed] [Google Scholar]
  • 73.UK Prospective Diabetes Study Group Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet. 1998;352:854–865. [PubMed] [Google Scholar]
  • 74.CDC Diabetes Cost-effectiveness Research Group Cost-effectiveness of intensive glycaemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287:2542–2551. doi: 10.1001/jama.287.19.2542. [DOI] [PubMed] [Google Scholar]
  • 75.Brown J.B., Pedula K.L., Bakst A.W. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med. 1999;159:1873–1880. doi: 10.1001/archinte.159.16.1873. [DOI] [PubMed] [Google Scholar]
  • 76.American Diabetes Association Economic consequences of type 2 diabetes in the US in 1997. Diabetes Care. 1998;83:2635–2642. doi: 10.2337/diacare.21.2.296. [DOI] [PubMed] [Google Scholar]
  • 77.Villarreal-Rios E., Salinas-Martinez A.M., Medina-Jauregui A., Garza- Elizondo M.E., Nunez-Rocha G., Chuy-Diaz E.R. The cost of diabetes mellitus and its impact on health spending in Mexico. Arch Med Res. 2000;31:511–514. doi: 10.1016/s0188-4409(00)00095-3. [DOI] [PubMed] [Google Scholar]
  • 78.Bagust A., Hopkinson P.K., Maslove L., Currie C.J. The projected health care burden of type 2 diabetes in the UK from 2000 to 2060. Diabet Med. 2002;19(suppl. 4):1–5. doi: 10.1046/j.1464-5491.19.s4.2.x. [DOI] [PubMed] [Google Scholar]
  • 79.Palmer A.J., Roze S., Comte S., Cabrières L. Cost-effectiveness of intensive lifestyle changes or metformin in overweight, glucose-intolerant patients: modelling the long-term implications of the diabetes prevention Program in the French, German and UK settings [Abstract] Diabetologia. 2002;45(suppl.2):A303. [Google Scholar]
  • 80.Diabetes Prevention Program Research Group Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care. 2003;26:36–47. doi: 10.2337/diacare.26.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Owada M., Hanaoka Y., Tanimoto Y., Kitagawa T. Descriptive epidemiology of non-insulin dependent diabetes mellitus detected by urine glucose screening in school children in Japan. Acta Paediatr Jpn. 1990;32:716–724. doi: 10.1111/j.1442-200x.1990.tb00910.x. [DOI] [PubMed] [Google Scholar]
  • 82.McKinley J., Marceau L. US public health and the 21st century: diabetes mellitus. Lancet. 2000;356:757–761. doi: 10.1016/S0140-6736(00)02641-6. [DOI] [PubMed] [Google Scholar]
  • 83.Lindstrom J., Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes. Diabetes Care. 2003;26:725–731. doi: 10.2337/diacare.26.3.725. [DOI] [PubMed] [Google Scholar]
  • 84.Finnish Diabetes Association. DEHKO: Development programme for the prevention and care of diabetes in Finland 2000-2010. Available at http://www.diabetes.fi (accessed April 7, 2003).

Articles from Diabetes & Metabolism are provided here courtesy of Elsevier

RESOURCES